To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Druglikeness is a qualitative concept used in drug design for how "druglike" a substance is. It is estimated from the molecular structure before the substance is even synthesized and tested. A druglike molecule has properties like this:
Additional recommended knowledge
Based on this information, druglikeness indexes can be constructed. A good druglikeness index gives the green light to known, effective drugs but rejects most other known chemicals. Ideally, using a druglikeness index leads to rejecting nonviable lead compounds before they are even synthesized. One of the traditional rules of thumb is Lipinski's Rule of Five.
Also, other factors such as substructures with known toxic, mutagenic or teratogenic affect the usefulness of a designed molecule. In fact, several poisons have a good druglikeness. Natural toxins are used in pharmacological research to find out their mechanism of action, and if it could be exploited for beneficial purposes.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Druglikeness". A list of authors is available in Wikipedia.|